{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:07:16Z","timestamp":1793192836133,"version":"4.5.0"},"reference-count":190,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.bioorg.2021.104998","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T11:48:24Z","timestamp":1621424904000},"page":"104998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus"],"prefix":"10.1016","volume":"113","author":[{"given":"Ajay","family":"Manaithiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozair","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrinda","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd.","family":"Javed Naim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran A","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bioorg.2021.104998_b0005","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2337\/diab.43.6.735","article-title":"Insulin Resistance or Insulin Deficiency: Which Is the Primary Cause of NIDDM?","volume":"43","author":"Taylor","year":"1994","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.bioorg.2021.104998_b0010","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2337\/diacare.15.3.318","article-title":"Pathogenesis of NIDDM: A Balanced Overview","volume":"15","author":"DeFronzo","year":"1992","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0015","doi-asserted-by":"crossref","DOI":"10.4172\/2167-065X.1000117","article-title":"Therapeutic Targets for Diabetes Mellitus: An Update","volume":"3","author":"Tiwari","year":"2014","journal-title":"Clin. Pharmacol. Biopharm."},{"issue":"10","key":"10.1016\/j.bioorg.2021.104998_b0020","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4066\/AMJ.2013.1791","article-title":"India Towards Diabetes Control: Key Issues","volume":"6","author":"Kumar","year":"2013","journal-title":"Australasian Med. J."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0025","doi-asserted-by":"crossref","DOI":"10.4172\/2155-6156.1000541","article-title":"Classification, Pathophysiology, Diagnosis and Management of Diabetes Mellitus","volume":"6","author":"Baynest","year":"2015","journal-title":"J. Diabetes Metabol."},{"key":"10.1016\/j.bioorg.2021.104998_b0030","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2020. https:\/\/www.cdc.gov\/diabetes\/data\/statistics\/2014statisticsreport.html. (Accessed June 23, 2020)."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104998_b0035","doi-asserted-by":"crossref","first-page":"184","DOI":"10.12968\/bjon.2007.16.3.22974","article-title":"Diabetes Mellitus, Part 1: Physiology and Complications","volume":"16","author":"Nair","year":"2007","journal-title":"Brit. J. Nurs."},{"key":"10.1016\/j.bioorg.2021.104998_b0040","series-title":"Rang and Dale\u2019s pharmacology dinburgh","first-page":"377","author":"Rang","year":"2012"},{"key":"10.1016\/j.bioorg.2021.104998_b0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/B978-0-12-816864-6.00003-1","article-title":"Pathophysiology of Diabetes","author":"Moini","year":"2019","journal-title":"Epidemiol. Diabetes"},{"key":"10.1016\/j.bioorg.2021.104998_b0050","article-title":"Type 2 Diabetes Mellitus","author":"Khardori","year":"2020","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0055","article-title":"Diabetes mellitus: a major concern of modern lifestyle","volume":"7","author":"Pandey","year":"2017","journal-title":"Int. J. Inst. Pharm. Life Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104998_b0060","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and In Nondiabetic Subjects with And Without Prior Myocardial Infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"New Eng. J. Med."},{"issue":"15","key":"10.1016\/j.bioorg.2021.104998_b0065","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1056\/NEJM199910073411506","article-title":"Nephropathy in Patients with Type 2 Diabetes Mellitus","volume":"341","author":"Ritz","year":"1999","journal-title":"New Eng. J. Med."},{"issue":"12","key":"10.1016\/j.bioorg.2021.104998_b0070","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diacare.15.12.1844","article-title":"Diabetic Retinopathy: A Clinical Overview","volume":"15","author":"Davis","year":"1992","journal-title":"Diabetes Care"},{"issue":"Supplement 3","key":"10.1016\/j.bioorg.2021.104998_b0075","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.2337\/diabetes.53.suppl_3.S16","article-title":"Five Stages of Evolving Beta-Cell Dysfunction During Progression to Diabetes","volume":"53","author":"Weir","year":"2004","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.bioorg.2021.104998_b0080","doi-asserted-by":"crossref","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":"\u0392-Cell Failure in Diabetes and Preservation by Clinical Treatment","volume":"28","author":"Wajchenberg","year":"2007","journal-title":"Endocr. Rev."},{"issue":"8","key":"10.1016\/j.bioorg.2021.104998_b0085","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0026-0495(89)90064-4","article-title":"Similar Reduction of First- And Second-Phase B-Cell Responses at Three Different Glucose Levels in Type II Diabetes and The Effect of Gliclazide Therapy","volume":"38","author":"Hosker","year":"1989","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0090","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Cell Deficit and Increased -Cell Apoptosis in Humans with Type 2 Diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.bioorg.2021.104998_b0095","first-page":"687","article-title":"Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies","volume":"37","author":"Brunetti","year":"2012","journal-title":"P T."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0100","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy And Safety Of Liraglutide 3.0 Mg In Individuals With Overweight Or Obesity And Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.bioorg.2021.104998_b0105","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5001\/omj.2012.68","article-title":"Type 2 Diabetes Mellitus: A Review of Current Trends","volume":"27","author":"Olokoba","year":"2012","journal-title":"Oman Med. J."},{"key":"10.1016\/j.bioorg.2021.104998_b0110","first-page":"309","article-title":"Intestinal Sensing of Nutrients","author":"Tolhurst","year":"2011","journal-title":"Handbook of Exp. Pharmacol."},{"key":"10.1016\/j.bioorg.2021.104998_b0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.peptides.2015.06.012","article-title":"Lipid derivatives activ ate GPR119 and trigger GLP-1 secretion in primary murine L-cells","volume":"77","author":"Moss","year":"2016","journal-title":"Peptides"},{"issue":"3","key":"10.1016\/j.bioorg.2021.104998_b0120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1517\/13543784.2012.657797","article-title":"The Therapeutic Potential of GPR119 Agonists for Type 2 Diabetes","volume":"21","author":"Ohishi","year":"2012","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"3","key":"10.1016\/j.bioorg.2021.104998_b0125","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1124\/jpet.118.250019","article-title":"DS-8500A, An Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 And Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats","volume":"367","author":"Matsumoto","year":"2018","journal-title":"J. Pharmacol. Exper. Therap."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0130","doi-asserted-by":"crossref","DOI":"10.1210\/en.2007-0966","article-title":"A Role for Intestinal Endocrine Cell-Expressed G Protein-Coupled Receptor 119 In Glycemic Control by Enhancing Glucagon-Like Peptide-1 And Glucose-Dependent Insulinotropic Peptide Release","volume":"149","author":"Chu","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.bioorg.2021.104998_b0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/dom.13008","article-title":"Monoacylglycerol Signalling and ABHD6 In Health and Disease","volume":"19","author":"Poursharifi","year":"2017","journal-title":"Diabetes, Obesity Metabol."},{"key":"10.1016\/j.bioorg.2021.104998_b0140","series-title":"GPR119 agonism increases glucagon secretion during insulin-induced hypoglycemia","author":"Li","year":"2018"},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0145","doi-asserted-by":"crossref","DOI":"10.2337\/db08-1237","article-title":"GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion from The Intestinal Enteroendocrine L-Cell","volume":"58","author":"Lauffer","year":"2009","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.bioorg.2021.104998_b0150","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00269.2012","article-title":"Regulation of GPR119 Receptor Activity with Endocannabinoid-Like Lipids","volume":"303","author":"Syed","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metabol."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104998_b0155","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1677\/JOE-08-0453","article-title":"GPR119 Is Required For Physiological Regulation Of Glucagon-Like Peptide-1 Secretion But Not For Metabolic Homeostasis","volume":"201","author":"Lan","year":"2009","journal-title":"J. Endocrinol."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104998_b0160","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.bbrc.2004.11.120","article-title":"Lysophosphatidylcholine Enhances Glucose-Dependent Insulin Secretion Via An Orphan G-Protein-Coupled Receptor","volume":"326","author":"Soga","year":"2005","journal-title":"Biochem. Biophys. Res. Comm."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0165","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1089\/adt.2018.849","article-title":"Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119","volume":"16","author":"Nieto","year":"2018","journal-title":"Assay Drug Dev. Technol."},{"issue":"6","key":"10.1016\/j.bioorg.2021.104998_b0170","doi-asserted-by":"crossref","DOI":"10.1021\/jm200003p","article-title":"Activation Of The G-Protein-Coupled Receptor 119: A Conformation-Based Hypothesis For Understanding Agonist Response","volume":"54","author":"McClure","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104998_b0175","unstructured":"International Diabetes Federation, IDF Diabetes Atlas, seventh ed., Brussels, Belgium, 2015. http:\/\/www.diabetesatlas.org."},{"issue":"6","key":"10.1016\/j.bioorg.2021.104998_b0180","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4239\/wjd.v3.i6.110","article-title":"Trends in Prevalence of Diabetes in Asian Countries","volume":"3","author":"Ramachandran","year":"2012","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.bioorg.2021.104998_b0185","unstructured":"International Diabetes Federation, The Diabetes Atlas, sixth ed., Africa at a Glance, 2013."},{"key":"10.1016\/j.bioorg.2021.104998_b0190","unstructured":"World Health Organization, Diabetes, Fact sheet N\u00b0312. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes 2020."},{"key":"10.1016\/j.bioorg.2021.104998_b0195","unstructured":"IDF Diabetes Atlas 2019, 9. https:\/\/www.idf.org\/aboutdiabetes\/what-is-diabetes\/facts-figures.html."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0200","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global Prevalence of Diabetes: Estimates for The Year 2000 And Projections For 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bioorg.2021.104998_b0205","unstructured":"World Health Organization, Obesity and overweight, 2020, Fact sheets www.who.int\/newsroom\/fact-sheets\/detail\/obesity-and-overweight."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0210","first-page":"560","article-title":"Antagonist: diabetes and insulin resistance - philosophy, science, and the multiplier hypothesis","volume":"125","author":"Robertson","year":"1995","journal-title":"J. Lab. Clin. Med."},{"issue":"8","key":"10.1016\/j.bioorg.2021.104998_b0215","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2337\/diab.43.8.1066","article-title":"Insulin Action, Diabetogenes, And the Cause of Type II Diabetes","volume":"43","author":"Kahn","year":"1994","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.bioorg.2021.104998_b0220","first-page":"3","article-title":"Pathophysiology of Type 2 Diabetes and The Role of Incretin Hormones and Beta-Cell Dysfunction","volume":"20","author":"Fujioka","year":"2007","journal-title":"J. Am. Acad. Phys. Assist."},{"key":"10.1016\/j.bioorg.2021.104998_b0225","first-page":"475","article-title":"Type 2 diabetes: pathophysiology and clinical features","volume":"1","author":"Hackett","year":"2009","journal-title":"Pharm. J. Clin. Pharmacist"},{"key":"10.1016\/j.bioorg.2021.104998_b0230","series-title":"Textbook of Clinical Medicine [online]","author":"Kumar","year":"2002"},{"issue":"37","key":"10.1016\/j.bioorg.2021.104998_b0235","doi-asserted-by":"crossref","first-page":"16009-","DOI":"10.1073\/pnas.1006639107","article-title":"Paracrinology of Islets and The Paracrinopathy Of Diabetes","volume":"107","author":"Unger","year":"2010","journal-title":"Proc. Nat. Acad, Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104998_b0240","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1210\/jcem.84.4.5612","article-title":"Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, And Treatmen","volume":"84","author":"Mahler","year":"1999","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.bioorg.2021.104998_b0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1463-1326.2008.00939.x","article-title":"Relationship between \u0392-Cell Mass and Diabetes Onset","volume":"10","author":"Matveyenko","year":"2008","journal-title":"Diabetes, Obesity Metabol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104998_b0250","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2337\/db15-0779","article-title":"Insulitis And \u0392-Cell Mass in The Natural History of Type 1 Diabetes","volume":"65","author":"Campbell-Thompson","year":"2015","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0255","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1210\/jc.2004-1133","article-title":"\u0392-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis","volume":"90","author":"Ferrannini","year":"2005","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"9","key":"10.1016\/j.bioorg.2021.104998_b0260","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ng.2385","article-title":"Large-Scale Association Analyses Identify New Loci Influencing Glycemic Traits And Provide Insight Into The Underlying Biological Pathways","volume":"44","author":"Scott","year":"2012","journal-title":"Nat. Genetics"},{"issue":"9","key":"10.1016\/j.bioorg.2021.104998_b0265","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ng.2383","article-title":"Large-Scale Association Analysis Provides Insights into The Genetic Architecture and Pathophysiology of Type 2 Diabetes","volume":"44","author":"Morris","year":"2012","journal-title":"Nat. Genetics"},{"issue":"3","key":"10.1016\/j.bioorg.2021.104998_b0270","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2265.2002.01610.x","article-title":"Genetics of Type 2 Diabetes and Insulin Resistance: Knowledge from Human Studies","volume":"57","author":"McIntyre","year":"2002","journal-title":"Clin. Endocrinol"},{"issue":"6","key":"10.1016\/j.bioorg.2021.104998_b0275","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/ng2043","article-title":"A Variant in CDKAL1 Influences Insulin Response and Risk of Type 2 Diabetes","volume":"39","author":"Steinthorsdottir","year":"2007","journal-title":"Nat. Genetics"},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0280","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/ng.288","article-title":"Common Variant In MTNR1B Associated With Increased Risk Of Type 2 Diabetes And Impaired Early Insulin Secretion","volume":"41","author":"Lyssenko","year":"2008","journal-title":"Nat. Genetics"},{"issue":"7","key":"10.1016\/j.bioorg.2021.104998_b0285","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ng.609","article-title":"Twelve Type 2 Diabetes Susceptibility Loci Identified Through Large-Scale Association Analysis","volume":"42","author":"Voight","year":"2010","journal-title":"Nat. Genetics"},{"issue":"4","key":"10.1016\/j.bioorg.2021.104998_b0290","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2337\/diabetes.53.4.1141","article-title":"Genetic Variation Near The Hepatocyte Nuclear Factor-4 Gene Predicts Susceptibility To Type 2 Diabetes","volume":"53","author":"Silander","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.bioorg.2021.104998_b0295","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2337\/db12-0819","article-title":"Insights Into The Molecular Mechanism For Type 2 Diabetes Susceptibility At The KCNQ1 Locus From Temporal Changes In Imprinting Status In Human Islets","volume":"62","author":"Travers","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.bioorg.2021.104998_b0300","first-page":"1","article-title":"Early-Life Origins of Type 2 Diabetes: Fetal Programming of The Beta-Cell Mass","author":"Portha","year":"2011","journal-title":"Exp. Diabetes Res."},{"issue":"9","key":"10.1016\/j.bioorg.2021.104998_b0305","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jama.2011.207","article-title":"Functional variants of the HMGA1 gene and type 2 diabetes mellitus","volume":"305","author":"Chiefari","year":"2011","journal-title":"J. Am. Med. Assoc."},{"issue":"9","key":"10.1016\/j.bioorg.2021.104998_b0310","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archinte.159.9.957","article-title":"Body Weight Patterns From 20 To 49 Years of Age and Subsequent Risk for Diabetes Mellitus","volume":"159","author":"Brancati","year":"1999","journal-title":"Arch. Int. Med."},{"issue":"6","key":"10.1016\/j.bioorg.2021.104998_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100783","article-title":"PTPRT Regulates High-Fat Diet-Induced Obesity and Insulin Resistance","volume":"9","author":"Feng","year":"2014","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.bioorg.2021.104998_b0320","doi-asserted-by":"crossref","first-page":"d169","DOI":"10.2741\/A272","article-title":"Free Fatty Acids FFA A Link Between Obesity and Insulin Resistance","volume":"3","author":"Boden","year":"1998","journal-title":"Front. Biosci."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104998_b0325","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ecl.2008.06.007","article-title":"Obesity and Free Fatty Acids","volume":"37","author":"Boden","year":"2008","journal-title":"Endocrinol. Metabol. Clin. North Am."},{"issue":"21","key":"10.1016\/j.bioorg.2021.104998_b0330","doi-asserted-by":"crossref","DOI":"10.1001\/archinternmed.2010.356","article-title":"Bidirectional Association Between Depression and Type 2 Diabetes Mellitus in Women","volume":"170","author":"Pan","year":"2010","journal-title":"Arch. Int. Med."},{"issue":"12","key":"10.1016\/j.bioorg.2021.104998_b0335","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1007\/s00125-010-1874-x","article-title":"Type 2 Diabetes Mellitus as A Risk Factor for The Onset of Depression: A Systematic Review and Meta-Analysis","volume":"53","author":"Nouwen","year":"2010","journal-title":"Diabetologia"},{"issue":"15","key":"10.1016\/j.bioorg.2021.104998_b0340","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year Follow-Up of Intensive Glucose Control in Type 2 Diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"New Eng. J. Med."},{"issue":"9131","key":"10.1016\/j.bioorg.2021.104998_b0345","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive Blood-Glucose Control with Sulphonylureas Or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33)","volume":"352","author":"Turner","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bioorg.2021.104998_b0350","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1517\/14728222.8.2.165","article-title":"G-Protein-Coupled Receptors: New Approaches to Maximise the Impact of Gpcrs In Drug Discovery","volume":"8","author":"Davey","year":"2004","journal-title":"Expert Opinion Therap. Targets"},{"issue":"6953","key":"10.1016\/j.bioorg.2021.104998_b0355","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature01921","article-title":"Oleylethanolamide Regulates Feeding And Body Weight Through Activation Of The Nuclear Receptor PPAR-\u0391","volume":"425","author":"Fu","year":"2003","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bioorg.2021.104998_b0360","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0014-5793(03)01196-7","article-title":"Seven Evolutionarily Conserved Human Rhodopsin G Protein-Coupled Receptors Lacking Close Relatives","volume":"554","author":"Fredriksson","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bioorg.2021.104998_b0365","unstructured":"G. Griffin, Methods for identification of modulators of OSGPR116 activity, U.S. Patent 7083933B1, August 01, (2006)."},{"issue":"6","key":"10.1016\/j.bioorg.2021.104998_b0370","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1210\/en.2006-1608","article-title":"A Role For \u0392-Cell-Expressed G Protein-Coupled Receptor 119 In Glycemic Control by Enhancing Glucose-Dependent Insulin Release","volume":"148","author":"Chu","year":"2007","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.bioorg.2021.104998_b0375","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2006.02.004","article-title":"Deorphanization of A G Protein-Coupled Receptor For Oleoylethanolamide And Its Use In The Discovery Of Small-Molecule Hypophagic Agents","volume":"3","author":"Overton","year":"2006","journal-title":"Cell Metabol."},{"key":"10.1016\/j.bioorg.2021.104998_b0380","unstructured":"Z.L. Chu, J.N. Leonard, H.A. Al. Shamma, M.J. Robert, Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level, WIPO Patent WO2006076231A8, September 21, (2016)."},{"issue":"7","key":"10.1016\/j.bioorg.2021.104998_b0385","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1358\/dnp.2010.23.7.1468395","article-title":"The Significance of GPR119 Agonists as A Future Treatment for Type 2 Diabetes","volume":"23","author":"Dhayal","year":"2010","journal-title":"Drug News Perspect."},{"issue":"12","key":"10.1016\/j.bioorg.2021.104998_b0390","first-page":"1646","article-title":"Activation of Proglucagon Gene Transcription by Protein Kinase-A in A Novel Mouse Enteroendocrine Cell Line","volume":"8","author":"Drucker","year":"1994","journal-title":"Molecular Endocrinol."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104998_b0395","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.bbrc.2006.10.076","article-title":"Expression and Distribution of Gpr119 In the Pancreatic Islets of Mice and Rats: Predominant Localization in Pancreatic Polypeptide-Secreting PP-Cells","volume":"351","author":"Sakamoto","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0400","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.metabol.2012.06.010","article-title":"GPR119 Expression In Normal Human Tissues And Islet Cell Tumors: Evidence For Its Islet-Gastrointestinal Distribution, Expression In Pancreatic Beta And Alpha Cells, And Involvement In Islet Function","volume":"62","author":"Odori","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.bioorg.2021.104998_b0405","unstructured":"J.A. Bonini, B.E. Borowsky, N. Adham, N. Boyle, T.O. Thompson, Methods of identifying compounds that bind to SNORF25 receptors. U.S. Patent 6468756B1, February 06, (2001)."},{"issue":"S1","key":"10.1016\/j.bioorg.2021.104998_b0410","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1038\/sj.bjp.0707529","article-title":"GPR119, A Novel G Protein-Coupled Receptor Target for The Treatment of Type 2 Diabetes and Obesity","volume":"153","author":"Overton","year":"2008","journal-title":"Brit. J. Pharmacol."},{"issue":"6860","key":"10.1016\/j.bioorg.2021.104998_b0415","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/35102582","article-title":"An Anorexic Lipid Mediator Regulated by Feeding","volume":"414","author":"Rodr\u00edguez de Fonseca","year":"2001","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bioorg.2021.104998_b0420","doi-asserted-by":"crossref","first-page":"R729","DOI":"10.1152\/ajpregu.00029.2005","article-title":"Mechanisms of Oleoylethanolamide-Induced Changes in Feeding Behavior And Motor Activity","volume":"289","author":"Proulx","year":"2005","journal-title":"Am. J. Physiol. -Regulatory, Integrative Comparative Physiol."},{"issue":"7","key":"10.1016\/j.bioorg.2021.104998_b0425","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/bjp.2008.337","article-title":"Endogenous and Synthetic Agonists of GPR119 Differ in Signalling Pathways and Their Effects on Insulin Secretion in Min6c4 Insulinoma Cells","volume":"155","author":"Ning","year":"2008","journal-title":"Brit. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.bioorg.2021.104998_b0430","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1517\/13543770903153878","article-title":"GPR119 Agonists for The Treatment of Type 2 Diabetes","volume":"19","author":"Jones","year":"2009","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2021.104998_b0435","unstructured":"J. Verma, A. Kumar, D. Shah, S.R. Bapuram, R.I. Patil, S. ALI, S.K. Rai, Thiazolopyridine derivatives as GPR119 agonists, Australia patent 2017246996B2, November 28, (2019)."},{"key":"10.1016\/j.bioorg.2021.104998_b0440","unstructured":"A.P. Gunjal, R.I. Patil, A. Kumar, P. Kumar, H. Rai, S.K. Rai, J. Verma, GPR119 agonist compounds, U.S. Patent 10208030B2, February 19, (2019)."},{"key":"10.1016\/j.bioorg.2021.104998_b0445","first-page":"May 23","article-title":"Modulators of the gpr119 receptor and the treatment of disorders related thereto","volume":"3323818A1","author":"Jones","year":"2018","journal-title":"Eur. Pat. Appl."},{"key":"10.1016\/j.bioorg.2021.104998_b0450","unstructured":"D.A. Wacker, J.A. Robl, X.Y. Ye, Y. Wang, Bicyclic heteroaryl compounds as gpr119 modulators, Brazil patent BR112012028445A2, July 19, (2016)."},{"key":"10.1016\/j.bioorg.2021.104998_b0455","article-title":"Novel compounds as modulators of gpr-119","volume":"2718279B1","author":"Nagarathnam","year":"2016","journal-title":"Eur. Pat. Appl."},{"key":"10.1016\/j.bioorg.2021.104998_b0460","unstructured":"C.J. Rabbat, I. Nashashibi, J. Song, J. Ma, X. Chen, Z. Zhao, Aril gpr119 agonists and uses thereof, Brazil Patent PI0914891, November 24, (2015)."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104998_b0465","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.lfs.2012.11.015","article-title":"Novel GPR119 Agonist AS1669058 Potentiates Insulin Secretion From Rat Islets And Has Potent Anti-Diabetic Effects In ICR And Diabetic Db\/Db Mice","volume":"92","author":"Oshima","year":"2013","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2021.104998_b0470","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1016\/j.ejmech.2011.04.014","article-title":"The First Pharmacophore Model for Potent G Protein-Coupled Receptor 119 Agonist","volume":"46","author":"Zhu","year":"2011","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2021.104998_b0475","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/00498254.2012.739719","article-title":"Evaluation of Drug Interactions of GSK1292263 (A GPR119 Agonist) With Statins: Fromin Vitrodata To Clinical Study Design","volume":"43","author":"Polli","year":"2012","journal-title":"Xenobiotica"},{"issue":"24","key":"10.1016\/j.bioorg.2021.104998_b0480","doi-asserted-by":"crossref","first-page":"10972","DOI":"10.1021\/jm301404a","article-title":"Discovery Of 6,7-Dihydro-5H-Pyrrolo[2,3-A]Pyrimidines As Orally Available G Protein-Coupled Receptor 119 Agonists","volume":"55","author":"Katamreddy","year":"2012","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2021.104998_b0485","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1016\/j.bmcl.2011.03.007","article-title":"Discovery Of Fused Bicyclic Agonists Of The Orphan G-Protein Coupled Receptor GPR119 With In Vivo Activity In Rodent Models Of Glucose Control","volume":"21","author":"Semple","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104998_b0490","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.bbrc.2010.08.141","article-title":"AS1907417, A Novel GPR119 Agonist, As an Insulinotropic and \u0392-Cell Preservative Agent for The Treatment of Type 2 Diabetes","volume":"400","author":"Yoshida","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104998_b0495","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/en.2010-1047","article-title":"GPR119 Regulates Murine Glucose Homeostasis Through Incretin Receptor-Dependent and Independent Mechanisms","volume":"152","author":"Flock","year":"2010","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.bioorg.2021.104998_b0500","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1016\/j.transproceed.2011.10.021","article-title":"Stimulating \u0392-Cell Replication and Improving Islet Graft Function by AR231453, A Gpr119 Agonist","volume":"43","author":"Gao","year":"2011","journal-title":"Transpl. Proc."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0505","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1172\/JCI43615","article-title":"Dual Elimination of The Glucagon And GLP-1 Receptors in Mice Reveals Plasticity in The Incretin Axis","volume":"121","author":"Ali","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"17","key":"10.1016\/j.bioorg.2021.104998_b0510","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/jm8006867","article-title":"Discovery Of The First Potent And Orally Efficacious Agonist Of The Orphan G-Protein Coupled Receptor 119","volume":"51","author":"Semple","year":"2008","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063861","article-title":"High-Throughput Screening for GPR119 Modulators Identifies A Novel Compound with Anti-Diabetic Efficacy in Db\/Db Mice","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.bioorg.2021.104998_b0520","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1432-2277.2011.01332.x","article-title":"Stimulating Beta Cell Replication and Improving Islet Graft Function by GPR119 Agonists","volume":"24","author":"Gao","year":"2011","journal-title":"Transplant Int."},{"key":"10.1016\/j.bioorg.2021.104998_b0525","unstructured":"B. Roberts, F. Gregoire, D. Karpf, Ed. Clemens, B. Lavan, J. Johnson, C. Mcwherter, R. Martin, M. Wilson, MBX-2982, a Novel, Oral GPR119 Agonist for the Treatment of Type 2 Diabetes: Results of Single and Multiple Dose Studies. Conference: 69th Annual Meeting of the American-Diabetes-Association, 58, 2009."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104998_b0530","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/EC-12-0079","article-title":"Upregulated Insulin Secretion in Insulin-Resistant Mice: Evidence of Increased Islet GLP1 Receptor Levels and GPR119-Activated GLP1 Secretion","volume":"2","author":"Ahlkvist","year":"2013","journal-title":"Endocrine Connect."},{"issue":"9","key":"10.1016\/j.bioorg.2021.104998_b0535","doi-asserted-by":"crossref","first-page":"E1409","DOI":"10.1210\/jc.2011-0647","article-title":"2-Oleoyl Glycerol Is A GPR119 Agonist and Signals GLP-1 Release in Humans","volume":"96","author":"Hansen","year":"2011","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0540","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/me.2009-0239","article-title":"N-Oleoyldopamine Enhances Glucose Homeostasis Through The Activation Of GPR119","volume":"24","author":"Chu","year":"2010","journal-title":"Mol. Endocrinol."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2021.104998_b0545","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bbrc.2011.10.141","article-title":"5-Hydroxy-Eicosapentaenoic Acid Is an Endogenous GPR119 Agonist and Enhances Glucose-Dependent Insulin Secretion","volume":"416","author":"Kogure","year":"2011","journal-title":"Biochem. Biophys. Res. Comm."},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0550","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.bmc.2016.10.030","article-title":"Novel 5-nitropyrimidine derivatives bearing endo-azabicyclic alcohols\/amines as potent GPR119 agonists","volume":"25","author":"Fang","year":"2017","journal-title":"Bio. Org. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104998_b0555","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s11030-017-9755-6","article-title":"Discovery Of 5-Methyl-2-(4-((4-(Methylsulfonyl) Benzyl) Oxy) Phenyl)-4-(Piperazin-1-Yl) Pyrimidine Derivatives as Novel GRP119 Agonists for The Treatment of Diabetes and Obesity","volume":"21","author":"Chen","year":"2017","journal-title":"Mol. Diversity"},{"issue":"16","key":"10.1016\/j.bioorg.2021.104998_b0560","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1016\/j.bmcl.2017.06.032","article-title":"Design, synthesis, and biological evaluation of aryl N-methoxyamide derivatives as GPR119 agonists","volume":"27","author":"Jang","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"22","key":"10.1016\/j.bioorg.2021.104998_b0565","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1016\/j.bmcl.2015.09.047","article-title":"Discovery Of The Oxazabicyclo [3.3.1]Nonane Derivatives As Potent And Orally Active GPR119 Agonists","volume":"25","author":"Dai","year":"2015","journal-title":"Bioorg. Med. Chem. Letts."},{"issue":"23","key":"10.1016\/j.bioorg.2021.104998_b0570","doi-asserted-by":"crossref","first-page":"126707","DOI":"10.1016\/j.bmcl.2019.126707","article-title":"One-Pot Synthesis of Novel Tert-Butyl-4-Substituted Phenyl-1H-1,2,3-Triazolo Piperazine\/Piperidine Carboxylates, Potential GPR119 Agonists","volume":"29","author":"Bashetti","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.bioorg.2021.104998_b0575","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.bmcl.2018.02.044","article-title":"Design and Synthesis of Novel and Potent GPR119 Agonists with A Spirocyclic Structure","volume":"28","author":"Harada","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"16","key":"10.1016\/j.bioorg.2021.104998_b0580","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.bmcl.2019.07.004","article-title":"Optimization of Oxadiazole Derivatives with A Spirocyclic Cyclohexane Structure as Novel GPR119 Agonists","volume":"29","author":"Harada","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.bioorg.2021.104998_b0585","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1021\/acsmedchemlett.5b00207","article-title":"Design Of Potent And Orally Active GPR119 Agonists For The Treatment Of Type II Diabetes","volume":"6","author":"Liu","year":"2015","journal-title":"ACS Med. Chem. Letts."},{"issue":"8","key":"10.1016\/j.bioorg.2021.104998_b0590","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.bmc.2018.02.032","article-title":"Design, Synthesis And Biological Evaluation Of Novel 7-Azaspiro[3.5]Nonane Derivatives As GPR119 Agonists","volume":"26","author":"Matsuda","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2021.104998_b0595","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.bmcl.2017.03.092","article-title":"Synthesis and Biological Evaluation of Pyrimidine Derivatives with Diverse Azabicyclic Ether\/Amine as Novel GPR119 Agonist","volume":"27","author":"Yang","year":"2017","journal-title":"Bioorg. Med. Chem. Letts."},{"key":"10.1016\/j.bioorg.2021.104998_b0600","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00543","article-title":"Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16","volume":"9","author":"Tyurenkov","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0605","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.bmcl.2017.01.091","article-title":"Discovery Of Phenyl Acetamides As Potent And Selective GPR119 Agonists","volume":"27","author":"Zhu","year":"2017","journal-title":"Bioorg. Med. Chem. Letts."},{"issue":"14","key":"10.1016\/j.bioorg.2021.104998_b0610","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1016\/j.bmc.2018.06.035","article-title":"Design And Synthesis Of Novel Pyrimido[5,4- D ]Pyrimidine Derivatives As GPR119 Agonist For Treatment Of Type 2 Diabetes","volume":"26","author":"Fang","year":"2018","journal-title":"Bioorg. Med. Chemi."},{"issue":"16","key":"10.1016\/j.bioorg.2021.104998_b0615","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1016\/j.bmc.2017.06.014","article-title":"Novel 3 H -[1,2,3]Triazolo[4,5- C ]Pyridine Derivatives As GPR119 Agonists: Synthesis And Structure-Activity\/Solubility Relationships","volume":"25","author":"Matsuda","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104998_b0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126855","article-title":"Design And Biological Evaluation Of Tetrahydropyridine Derivatives As Novel Human GPR119 Agonists","volume":"30","author":"Zuo","year":"2019","journal-title":"Bioorg. Med. Chem. Letts."},{"issue":"19","key":"10.1016\/j.bioorg.2021.104998_b0625","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1016\/j.bmcl.2018.08.010","article-title":"Discovery Of Novel Spiro[Chromane-2,4\u2032-Piperidine] Derivatives As Potent And Orally Bioavailable G-Protein-Coupled Receptor 119 Agonists","volume":"28","author":"Koshizawa","year":"2018","journal-title":"Bioorg. Med. Chem. Letts."},{"key":"10.1016\/j.bioorg.2021.104998_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103390","article-title":"Design and Synthesis of Tetrahydropyridopyrimidine Derivatives as Dual GPR119 and DPP-4 Modulators","volume":"94","author":"Fang","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.104998_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112017","article-title":"The Optimization Of Xanthine Derivatives Leading To HBK001 Hydrochloride As A Potent Dual Ligand Targeting DPP-IV And GPR119","volume":"188","author":"Li","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2021.104998_b0640","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1016\/j.bmcl.2015.04.102","article-title":"Discovery Of A Novel Trans-1,4-Dioxycyclohexane GPR119 Agonist Series","volume":"25","author":"Han","year":"2015","journal-title":"Bioorg. Med. Chem. Letts."},{"issue":"23","key":"10.1016\/j.bioorg.2021.104998_b0645","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1016\/j.bmcl.2017.10.046","article-title":"Synthesis and Biological Evaluation of Thiazole Derivatives as GPR119 Agonists","volume":"27","author":"Kim","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"15","key":"10.1016\/j.bioorg.2021.104998_b0650","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1016\/j.bmcl.2017.06.034","article-title":"Optimization of A Novel Series of Potent and Orally Bioavailable GPR119 Agonists","volume":"27","author":"Koshizawa","year":"2017","journal-title":"Bioorg. Med. Chem. Letts."},{"key":"10.1016\/j.bioorg.2021.104998_b0655","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejmech.2016.08.023","article-title":"Discovery of Novel Xanthine Compounds Targeting DPP-IV and GPR119 As Anti-Diabetic Agents","volume":"124","author":"Li","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104998_b0660","doi-asserted-by":"crossref","first-page":"1800267","DOI":"10.1002\/ardp.201800267","article-title":"Discovery and Biological Evaluation of Novel G Protein-Coupled Receptor 119 Agonists for Type 2 Diabetes","volume":"352","author":"Zhou","year":"2019","journal-title":"Arch. Pharm."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0665","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/acsmedchemlett.8b00073","article-title":"Discovery Of MK-8282 As A Potent G-Protein-Coupled Receptor 119 Agonist For The Treatment Of Type 2 Diabetes","volume":"9","author":"Neelamkavil","year":"2018","journal-title":"ACS Med. Chem. Letts."},{"issue":"15","key":"10.1016\/j.bioorg.2021.104998_b0670","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1016\/j.bmcl.2016.06.050","article-title":"Design And Synthesis Of 1H-Pyrazolo[3,4-C]Pyridine Derivatives As A Novel Structural Class Of Potent GPR119 Agonists","volume":"26","author":"Matsuda","year":"2016","journal-title":"Bioorg. Med. Chem. Letts."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0675","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00044-017-1808-y","article-title":"In Silico Approaches to Explore Structure of New GPR 119 Agonists for Treatment of Type 2 Diabetes Mellitus","volume":"26","author":"Shiri","year":"2017","journal-title":"Med. Chem. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104998_b0680","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2337\/dc15-1585","article-title":"The Time Is Right for A New Classification System for Diabetes: Rationale and Implications of the \u0392-Cell\u2013Centric Classification Schema","volume":"39","author":"Schwartz","year":"2016","journal-title":"Diabetes Care"},{"issue":"9467","key":"10.1016\/j.bioorg.2021.104998_b0685","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(05)61032-X","article-title":"Type 2 Diabetes: Principles of Pathogenesis and Therapy","volume":"365","author":"Stumvoll","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bioorg.2021.104998_b0690","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.cell.2012.02.010","article-title":"Diabetes Mellitus and the \u0392 Cell: The Last Ten Years","volume":"148","author":"Ashcroft","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2021.104998_b0695","article-title":"Pathogenesis of Type 2 Diabetes Mellitus","author":"AlSaraj","year":"2015","journal-title":"Intech open Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0700","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2337\/diacare.27.1.17","article-title":"Glycemic Control From 1988 To 2000 Among U.S. Adults Diagnosed with Type 2 Diabetes: A Preliminary Report","volume":"27","author":"Koro","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bioorg.2021.104998_b0705","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.diabres.2019.03.024","article-title":"Treatment Of Type 2 Diabetes Mellitus Worldwide: Baseline Patient Characteristics In The Global DISCOVER Study","volume":"151","author":"Gomes","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0710","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jcem.87.5.7640","article-title":"The Impact of Clinical Trials on The Treatment of Diabetes Mellitus","volume":"87","author":"Nathan","year":"2002","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"17","key":"10.1016\/j.bioorg.2021.104998_b0715","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4239\/wjd.v7.i17.354","article-title":"Update on The Treatment of Type 2 Diabetes Mellitus","volume":"7","author":"Mar\u00edn-Pe\u00f1alver","year":"2016","journal-title":"World J. Diabetes"},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0720","first-page":"467","article-title":"Diabetes Drugs That Protect Pancreatic \u0392 Cells","volume":"3","author":"Nakatsuma","year":"2015","journal-title":"Integrative Mol. Med."},{"key":"10.1016\/j.bioorg.2021.104998_b0725","first-page":"253","article-title":"Primary Prevention and Risk Reduction for Cardiovascular\/Pulmonary Disorders-Preferred Practice Pattern 6A, Cardiopulmonary","author":"Irwin","year":"2001","journal-title":"Phys. Ther."},{"key":"10.1016\/j.bioorg.2021.104998_b0730","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/B978-0-12-803678-5.00108-9","article-title":"Diabetes Mellitus Treatment","author":"Khoo","year":"2017","journal-title":"Int. Encyclopedia Public Health"},{"issue":"12","key":"10.1016\/j.bioorg.2021.104998_b0735","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2008.09.004","article-title":"Type 2 Diabetes: New Genes, New Understanding","volume":"24","author":"Prokopenko","year":"2008","journal-title":"Trends Genet."},{"key":"10.1016\/j.bioorg.2021.104998_b0740","doi-asserted-by":"crossref","unstructured":"Standards of Medical Care in Diabetes (2009), Diabetes Care, (2008) 32 (Supplement_1), S13-S61.","DOI":"10.2337\/dc09-S013"},{"issue":"7121","key":"10.1016\/j.bioorg.2021.104998_b0745","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nature05482","article-title":"Mechanisms Linking Obesity to Insulin Resistance and Type 2 Diabetes","volume":"444","author":"Kahn","year":"2006","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.bioorg.2021.104998_b0750","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1021\/jm0306273","article-title":"Diabetes Mellitus: Pathogenesis and Treatment Strategies","volume":"47","author":"Skyler","year":"2004","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104998_b0755","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11154-008-9101-5","article-title":"\u0392-Cell Failure as A Complication of Diabetes","volume":"9","author":"Chang","year":"2008","journal-title":"Rev. Endocrine Metabol. Disorders"},{"issue":"6","key":"10.1016\/j.bioorg.2021.104998_b0760","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1210\/en.2007-0336","article-title":"G Protein-Coupled Receptors and Insulin Secretion: 119 And Counting","volume":"148","author":"Madiraju","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.bioorg.2021.104998_b0765","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ejphar.2015.06.031","article-title":"Sustained Wash-Resistant Receptor Activation Responses of GPR119 Agonists","volume":"762","author":"Hothersall","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104998_b0770","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.bbrc.2010.08.097","article-title":"Identification of A Novel GPR119 Agonist, AS1269574, With In Vitro And In Vivo Glucose-Stimulated Insulin Secretion","volume":"400","author":"Yoshida","year":"2010","journal-title":"Biochem. Biophys. Res. Comm."},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0775","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1124\/jpet.119.262675","article-title":"Oleoylethanolamide Increases Glycogen Synthesis and Inhibits Hepatic Gluconeogenesis Via the LKB1\/AMPK Pathway in Type 2 Diabetic Model","volume":"373","author":"Ren","year":"2020","journal-title":"J. Pharmacol. Exper. Ther."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104998_b0780","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1124\/jpet.115.222828","article-title":"Synergistic Effects of A GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice","volume":"353","author":"Al-Barazanji","year":"2015","journal-title":"J. Pharmacol. Exper. Therap."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104998_b0785","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S2213-8587(15)00462-3","article-title":"Future Glucose-Lowering Drugs for Type 2 Diabetes","volume":"4","author":"Bailey","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bioorg.2021.104998_b0790","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/B978-0-12-381517-0.00016-3","article-title":"GPR119 Agonists for The Potential Treatment of Type 2 Diabetes and Related Metabolic Disorders","volume":"84","author":"Shah","year":"2010","journal-title":"Incretins Insulin Secretion"},{"issue":"12","key":"10.1016\/j.bioorg.2021.104998_b0795","doi-asserted-by":"crossref","first-page":"18214","DOI":"10.1021\/acsomega.8b01941","article-title":"Deciphering G-Protein-Coupled Receptor 119 Agonists as Promising Strategy Against Type 2 Diabetes Using Systems Biology Approach","volume":"3","author":"Kaushik","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2021.104998_b0800","unstructured":"Blad, C. Catelijne, A quest for connections: ligands for the HCA2, adenosine A3 and GPR88 receptors. Doctoral thesis, Leiden University, 2012. http:\/\/hdl.handle.net\/1887\/20128."},{"issue":"8","key":"10.1016\/j.bioorg.2021.104998_b0805","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1073\/pnas.0230374100","article-title":"The G Protein-Coupled Receptor Repertoires of Human and Mouse","volume":"100","author":"Vassilatis","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"17","key":"10.1016\/j.bioorg.2021.104998_b0810","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1016\/j.bmcl.2014.07.020","article-title":"Synthesis And Biological Evaluation Of Thienopyrimidine Derivatives As GPR119 Agonists","volume":"24","author":"Jeon","year":"2014","journal-title":"Bioorg. Med. Chem. Letts."},{"key":"10.1016\/j.bioorg.2021.104998_b0815","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2019.02.012","article-title":"Adhesion G-Protein Coupled Receptors: Implications for Metabolic Function","volume":"198","author":"Olaniru","year":"2019","journal-title":"Pharmacol. Therap."},{"issue":"9","key":"10.1016\/j.bioorg.2021.104998_b0820","first-page":"1292","article-title":"Role of Free Fatty Acid Receptors in The Regulation of Energy Metabolism","volume":"1841","author":"Hara","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA) \u2013 Mol. Cell Biol. Lipids"},{"issue":"7","key":"10.1016\/j.bioorg.2021.104998_b0825","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.tips.2012.03.014","article-title":"GPR119 As A Fat Sensor","volume":"33","author":"Hansen","year":"2012","journal-title":"Trends Pharmacolog. Sci."},{"issue":"12","key":"10.1016\/j.bioorg.2021.104998_b0830","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1007\/s00125-016-4108-z","article-title":"Metabolic Effects of Orally Administered Small-Molecule Agonists of GPR55 And GPR119 In Multiple Low-Dose Streptozotocin-Induced Diabetic and Incretin-Receptor-Knockout Mice","volume":"59","author":"McKillop","year":"2016","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.bioorg.2021.104998_b0835","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158796","article-title":"Angelica Dahurica Extracts Improve Glucose Tolerance Through the Activation of GPR119","volume":"11","author":"Park","year":"2016","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.bioorg.2021.104998_b0840","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1210\/me.2015-1306","article-title":"GPR119 Agonist AS1269574 Activates TRPA1 Cation Channels to Stimulate GLP-1 Secretion","volume":"30","author":"Chepurny","year":"2016","journal-title":"Mol. Endocrinol."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104998_b0845","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4062\/biomolther.2018.011","article-title":"YH18968, A Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for The Treatment of Type 2 Diabetes Mellitus","volume":"26","author":"Han","year":"2018","journal-title":"Biomol. Therap."},{"key":"10.1016\/j.bioorg.2021.104998_b0850","unstructured":"J.A. Bonini, B.E. Borowsky, N. Adham, N. Boyle, T.O. Thompson, DNA encoding SNORF25 receptor, U.A. Patent 6221660B1, April 24, (2001)."},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0855","first-page":"91","article-title":"2- Ome -Lysophosphatidylcholine Analogues Are GPR119 Ligands and Activate Insulin Secretion From \u0392tc-3 Pancreatic Cells: Evaluation of Structure-Dependent Biological Activity","volume":"1863","author":"Drzazga","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA) \u2013 Mol. Cell Biol. Lipids"},{"issue":"11","key":"10.1016\/j.bioorg.2021.104998_b0860","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1016\/j.bmcl.2014.03.096","article-title":"Synthesis and Structure-Activity Relationship of Dihydrobenzofuran Derivatives as Novel Human GPR119 Agonists","volume":"24","author":"Ye","year":"2014","journal-title":"Bioorg. Med. Chem. Letts."},{"key":"10.1016\/j.bioorg.2021.104998_b0865","series-title":"Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes","author":"Russo","year":"2010"},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2021.104998_b0870","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The Incretin System and Its Role in Type 2 Diabetes Mellitus","volume":"297","author":"Holst","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bioorg.2021.104998_b0875","first-page":"8","article-title":"ZB-16, A Novel GPR119 Agonist, Relieves the Severity of Streptozotocin\u2013Nicotinamide-Induced Diabetes in Rats","author":"Tyurenkov","year":"2017","journal-title":"Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104998_b0880","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s12272-013-0209-0","article-title":"Novel GPR119 Agonist HD0471042 Attenuated Type 2 Diabetes Mellitus","volume":"37","author":"Ha","year":"2013","journal-title":"Arch. Pharm. Res."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104998_b0885","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/17460441.3.4.403","article-title":"GPR119 Agonists as Potential New Oral Agents for The Treatment of Type 2 Diabetes and Obesity","volume":"3","author":"Fyfe","year":"2008","journal-title":"Expert Opin. Drug Discov."},{"issue":"8","key":"10.1016\/j.bioorg.2021.104998_b0890","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1111\/j.1476-5381.2011.01755.x","article-title":"The Cytoprotective Effects of Oleoylethanolamide In Insulin-Secreting Cells Do Not Require Activation of GPR119","volume":"165","author":"Stone","year":"2012","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2021.104998_b0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.02.011","article-title":"GPR119 Is A Potent Regulator of Human Sebocyte Biology","author":"Markovics","year":"2020","journal-title":"J. Investigative Dermatol."},{"issue":"9","key":"10.1016\/j.bioorg.2021.104998_b0900","first-page":"1132","article-title":"Oleoyl-Lysophosphatidylinositol Enhances Glucagon-Like Peptide-1 Secretion from Enteroendocrine L-Cells Through GPR119. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of","volume":"1863","author":"Arifin","year":"2018","journal-title":"Lipids"},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0905","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-04633-5","article-title":"The Dual DPP4 Inhibitor and GPR119 Agonist HBK001 Regulates Glycemic Control and Beta Cell Function Ex And In Vivo","volume":"7","author":"Huan","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2021.104998_b0910","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcp.2016.08.018","article-title":"Biased Signaling Of Lipids and Allosteric Actions of Synthetic Molecules for GPR119","volume":"119","author":"Hassing","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2021.104998_b0915","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/B978-0-12-800101-1.00004-1","article-title":"Targeting GPR119 For the Potential Treatment of Type 2 Diabetes Mellitus","volume":"121","author":"Mo","year":"2014","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.bioorg.2021.104998_b0920","first-page":"1","article-title":"In Vivo Efficacy of HD0471953: A Novel GPR119 Agonist for The Treatment of Type 2 Diabetes Mellitus","author":"Kim","year":"2013","journal-title":"J. Diabetes Res."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104998_b0925","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/dom.13062","article-title":"Therapeutic Application of GPR119 Ligands in Metabolic Disorders","volume":"20","author":"Yang","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0930","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-018-0949-2","article-title":"GPR119 Agonist Enhances Gefitinib Responsiveness Through Lactate-Mediated Inhibition of Autophagy","volume":"37","author":"Im","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0935","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/jdi.12849","article-title":"G Protein-Coupled Receptor 119 Agonist DS-8500A Effects on Pancreatic \u0392-Cells in Japanese Type 2 Diabetes Mellitus Patients","volume":"10","author":"Watada","year":"2018","journal-title":"J. Diabetes Investigation"},{"issue":"6","key":"10.1016\/j.bioorg.2021.104998_b0940","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/jdi.12846","article-title":"Efficacy and Safety of The G Protein-Coupled Receptor 119 Agonist DS-8500A In Japanese Type 2 Diabetes Mellitus Patients with Inadequate Glycemic Control on Sitagliptin: A Phase 2 Randomized Placebo-Controlled Study","volume":"9","author":"Terauchi","year":"2018","journal-title":"J. Diabetes Investigation"},{"issue":"10","key":"10.1016\/j.bioorg.2021.104998_b0945","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40261-019-00825-1","article-title":"Effect Of DS-8500A, A Novel G Protein-Coupled Receptor 119 Agonist, On The Pharmacokinetics Of Rosuvastatin And Atorvastatin In Healthy Subjects","volume":"39","author":"Maekawa","year":"2019","journal-title":"Clin. Drug Investigation"},{"issue":"1","key":"10.1016\/j.bioorg.2021.104998_b0950","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000424","article-title":"Glucose-Lowering Effects And Safety Of DS-8500A, A G Protein-Coupled Receptor 119 Agonist, In Japanese Patients With Type 2 Diabetes: Results Of A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study","volume":"5","author":"Inagaki","year":"2017","journal-title":"BMJ Open Diabetes Res. Care"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821003758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821003758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:16:54Z","timestamp":1758615414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821003758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":190,"alternative-id":["S0045206821003758"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.104998","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.104998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104998"}}